AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseasePRNewsWire • 04/27/26
How A Small Biotech Name Just Rattled AbbVie's $18 Billion FranchiseInvestors Business Daily • 04/27/26
Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key MetricsZacks Investment Research • 04/24/26
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.PRNewsWire • 04/23/26
Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma's Most Durable Compounder?24/7 Wall Street • 04/21/26
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEXZacks Investment Research • 04/20/26
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological DiseasesGlobeNewsWire • 04/20/26
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the StockZacks Investment Research • 04/17/26
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit24/7 Wall Street • 04/17/26
3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the MarketThe Motley Fool • 04/15/26